EMERYVILLE, Calif., Feb. 17 /PRNewswire-FirstCall/ -- Bionovo Inc. (Nasdaq: BNVI) announced today the appointment of Bert O'Malley, M.D., to the company's Scientific Advisory Board. Dr. O'Malley, the recipient of the National Medal for Science in 2008, has extensive experience in academic research as well as with pharmaceutical and biotech companies.
"We are very excited to have Dr. O'Malley on the scientific advisory board as we are advancing our novel hormonal drug candidates," said Isaac Cohen, O.M.D., Bionovo's Chairman and CEO. He added, "Dr. O'Malley, a member of the National Academy of Sciences, and the recipient of the 2008 National Medal for Science, is a pioneer in biomedical research. Dr. O'Malley's landmark discoveries revealed the mechanism of hormone action and the critical importance of a previously undiscovered superfamily of mediators, the nuclear receptor coregulators. No doubt these discoveries have transformed the future of health and our ability to select safer, more targeted therapies for many critical indications. We are looking forward to collaborating with him on current and future indications involving nuclear receptors."
Dr. O'Malley states, "I'm delightfully surprised and impressed by the
selectivity, safety and clinical effects of Menerba, Bionovo's drug candidate
for menopausal hot flashes. To date, it is perhaps the most impressive SERM
I've encountered. The utilization of natural compounds with historical
clinical utility, and the targeted mechanism of action seems to result in a
safer drug with exciting clinical results. I believe this strategy is
propitious and will provide new therapies for many indications that currently
have unmet or poorly met medical needs. I hope our collaboration will further
expand therapeutic choices for a number of significant diseases with unmet
|SOURCE Bionovo Inc.|
Copyright©2009 PR Newswire.
All rights reserved